Insulet CorpPODD
Price$130.79Intrinsic value$354.86171% above price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $354.86median of 6 methods · middle span $250-$451based on filings through 30 Jun 2026
Market Price $130.79Price as of 1 Oct 2026
Margin of Safety +171.3%as of 1 Oct 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 26.5% (near-term consensus, capped) · years 2–5: 22.3%/yr (balance of the path).23.2% per year
Years 6–10: glide to demonstrated growth own history 83.3%, capped at 20%
Per-year rates
Yr 621.9%Yr 721.4%Yr 820.9%Yr 920.5%Yr 1020.0%
22.3% → 20.0%
Years 11–20: glide to long-run rate
Per-year rates
Yr 1118.3%Yr 1216.6%Yr 1314.9%Yr 1413.2%Yr 1511.5%Yr 169.8%Yr 178.1%Yr 186.4%Yr 194.7%Yr 203.0%
20.0% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 3 windows (5/6/7y)83.3%
Discount rate (cost of equity) 9.7%
Volatility vs market (adjusted beta)1.06

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetInsulet CorpPODDHealth Care
Valuation
P/E24.5×
P/S3.2×
P/B7.1×
EV / Revenue3.3×
EV / EBITDA18.3×
Profitability
Gross margin69.5%
Operating margin16.0%
Net margin12.3%
FCF margin9.6%
Returns
ROE26.4%
ROA11.9%
ROIC20.7%
Growth
Revenue growth (YoY)47.4%
5-yr fwd EPS growth23.2%
Financial strength
Debt / Equity0.65×
Current ratio2.48×
Altman Z-Score5.5
Interest coverage52.62×
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.